Cover Image
Market Research Report

A Global Product and Pipeline Analysis of Antiretroviral Drug Development for the Treatment of HIV/AIDS

Published by Frost & Sullivan Product code 307680
Published Content info 66 Pages
Delivery time: 1-2 business days
Price
Back to Top
A Global Product and Pipeline Analysis of Antiretroviral Drug Development for the Treatment of HIV/AIDS
Published: July 3, 2014 Content info: 66 Pages
Description

Antiretroviral Combinations Continue to Transform the Treatment Landscape

This research service focuses on antiviral/antiretroviral therapeutics for the treatment of HIV/AIDS. A product and pipeline assessment is provided for marketed and investigational products and combination regimens for the treatment of HIV infection. Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and global prevalence by region and country. Key market developments since Q1 2013 and key companies to watch are also included. This research service is an update of the 2013 research service titled Strategic Analysis of Antiviral Drug Development for Viral Hepatitis and HIV/AIDS.

Table of Contents
Product Code: NE48-01-00-00-00

Table of Contents

1. EXECUTIVE SUMMARY

  • 1. Key Market Developments since Q1 2013
  • 2. Key Findings
  • 3. Evolution of Standard of Care for HIV
  • 4. Key Companies to Watch

2. METHODOLOGY AND SCOPE

  • 1. Methodology and Scope

3. INTRODUCTION

  • 1. HIV Overview
  • 2. HIV Overview (continued)
  • 3. Prevalence of HIV/AIDS Globally and by Region
  • 4. Market Segmentation
  • 5. Market Segmentation (continued)

4. HIV/AIDS ANTIRETROVIRAL MARKET

  • 1. HIV/AIDS Antiretroviral Market-Competitive Landscape ofMarketed Products
  • 2. HIV/AIDS Antiretroviral Market-Competitive Landscape ofProducts in Development
  • 3. HIV/AIDS Antiretroviral Market-Product Launch and Patent Expiration Timeline
  • 4. HIV/AIDS Antiretroviral Market-Major Phase 3 Ongoing Trials
  • 5. HIV/AIDS Antiretroviral Market-Major Phase 3 Ongoing Trials (continued)
  • 6. HIV/AIDS Antiretroviral Market-Recent Pivotal Trial Results
  • 7. HIV/AIDS Antiretroviral Market-Recent Pivotal Trial Results (continued)
  • 8. Marketed Product Synopsis-Multi-class FDC Products
  • 9. Marketed Product Synopsis-Single-class FDC Products
  • 10. Marketed Product Synopsis-Single-entity Products
  • 11. Marketed Product Synopsis-Single-entity Products (continued)
  • 12. Marketed Product Synopsis-Single-entity Products (continued)
  • 13. Marketed Product Synopsis-Single-entity Products (continued)
  • 14. Marketed Product Synopsis-Single-entity Products (continued)
  • 15. Marketed Product Synopsis-Single-entity Products (continued)
  • 16. Marketed Product Synopsis-Single-entity Products (continued)
  • 17. Pipeline Synopsis-Late-stage Development Products
  • 18. Pipeline Synopsis-Late-stage Development Products (continued)
  • 19. Pipeline Synopsis-Late-stage Development Products (continued)
  • 20. Pipeline Synopsis-Late-stage Development Products (continued)
  • 21. Pipeline Synopsis-Late-stage Development Products (continued)
  • 22. Pipeline Synopsis-Late-stage Development Products (continued)
  • 23. Pipeline Synopsis-Early Clinical Development Products
  • 24. Pipeline Synopsis-Early Development Products
  • 25. Pipeline Synopsis-Early Development Products (continued)
  • 26. Pipeline Synopsis-Early Development Products (continued)

5. CONCLUSIONS AND RECOMMENDATIONS

  • 1. Conclusions and Recommendations
  • 2. Legal Disclaimer

6. APPENDIX

  • 1. Decision Support Database-Prevalence of HIV Infection
  • 2. Decision Support Database-Prevalence of HIV Infection (continued)
  • 3. Decision Support Database-Prevalence of HIV Infection (continued)
  • 4. Decision Support Database-Prevalence of HIV Infection (continued)
  • 5. Decision Support Database-Prevalence of HIV Infection (continued)
  • 6. Decision Support Database-Prevalence of HIV Infection (continued)
  • 7. Decision Support Database-Prevalence of HIV Infection (continued)
  • 8. Decision Support Database-Prevalence of HIV Infection (continued)
  • 9. Decision Support Database-Prevalence of HIV Infection (continued)
  • 10. Decision Support Database-Prevalence of HIV Infection (continued)

7. THE FROST & SULLIVAN STORY

  • 1. The Frost & Sullivan Story
  • 2. Value Proposition: Future of Your Company & Career
  • 3. Global Perspective
  • 4. Industry Convergence
  • 5. 360° Research Perspective
  • 6. Implementation Excellence
  • 7. Our Blue Ocean Strategy
Back to Top